Introduction
Tuberculosis (TB) has been declared ag lobal health emergency by the World Health Organization (WHO). It is estimated that about one third of the world's population is currently infected with the responsible actinobacteria Mycobacterium tuberculosis (Mtb). [1] Resistance of Mtb to availablea ntibiotics has increased drastically,a nd multidrug-resistant( MDR) strains of Mtb as well as extensively drug-resistant( XDR) strains are becoming am ajor health problem worldwide. [1] Furthermore, cases have recently been reported where no availablef irst-and secondline drugs are effective,a nd this has led to the term totally drug-resistant (TDR) TB.
[2] Resistant strains of Mtb require longer treatment, whichm ay lead to interruption of therapy and, in turn, lead to furtherd rug resistance. The usual drug regimen for TB at present consists of antibioticsd iscovered more than 60 years ago, and includes isoniazid, rifampicin, pyrazinamide, and ethambutol. [3] These antibiotics act by disruption of cell wall synthesis [4] and inhibition of RNA synthesis.
[4c, 5] It was quickly discovered that monotherapy led to resistance in the bacteria, and therefore the recommended TB treatment today utilizes ac ombinationo ft he four first-line drugs for two months, and thereafter ap harmacotherapy with rifampicin and isoniazid for an additional four months. [3] Considering the long treatment time, the adverse effects associated with the drugs, and the problemsw ith resistants trains, it is clear that there is ag reat need for novel antibioticst hat possessn ew antitubercular modes of action and that can be used in combination with existing drugs.
Proteasomes are responsible for degrading proteins, and so help maintain intracellular protein homeostasis.
[6] The human proteasome consists of ac ylindrical 26S particle composed of a2 0S core catalytic component capped at one or both ends with a1 9S regulatory subunit, which recognizes and binds the substrate protein.I ne ukaryotic proteasomes, the 20S core particle is composed of four heptameric rings, of which the two inner rings are made up of seven different b-subunits, with only three of them responsible for the proteolytic activity (b1, b2, b5, with peptidyl-glutamyl-peptide-hydrolyzing, trypsin-like and chymotrypsin-like activities, respectively). [7] The Mtb proteasome displays the same overall structure as the proteasomes of eukaryotic systems.
[8] However,p rokaryotic 20S proThis is the first report of 5-styryl-oxathiazol-2-ones as inhibitors of the Mycobacterium tuberculosis (Mtb)p roteasome. As part of the study,t he structure-activity relationship of oxathiazolones as Mtb proteasome inhibitors has been investigated. Furthermore, the preparedc ompounds displayed ag ood selectivity profile for Mtb compared to the human proteasome.T he 5-styryl-oxathiazol-2-one inhibitors identified showed little activity against replicating Mtb,b ut were rapidlyb actericidal against nonreplicating bacteria. (E)-5-(4-Chlorostyryl)-1,3,4-oxathiazol-2-one) was most effective,r educing the colony-forming units (CFU)/mLb elow the detection limit in only seven days at all concentrations tested. The resultss uggest that this new class of Mtb proteasome inhibitors has the potential to be further developed into novel antitubercular agents for synergistic combination therapies with existing drugs.
teasomes,i ncluding those from Mtb,h aveb een shown to have open cylindrical ends, in contrast to the tighter ends of eukaryotic proteasomes, and possess only one typeofb-subunit, usually resembling the eukaryotic b5c hymotrypsin-like structure. [8] [9] Proteolytic activity involves the b-hydroxyl group of the N-terminal threonine, which is present in the active site of proteasome subunits. [7a-d] In many diseases,s uch as cancer, auto-immune diseases, and neurodegenerative diseases,c ellsa ccumulate various proteins, and the human proteasome hasthus emerged as apromising therapeutic target. [6a, 7a] The first human proteasome inhibitor,B ortezomib (Velcade), was approved for clinical use in the USA in 2003 and in Europei n2 004 for the treatment of multiple myeloma (Figure 1 ). The X-ray structure of the yeast proteasome in complex with the compound was reported in 2006, giving valuable insights into its binding interactions. [10] Serioust oxicitya ssociatedw ith peptidyl boronates, such as Bortezomib, is mainly due to the inhibition of the b5s ubunit of the human proteasome, [11] precluding the use for treatment of, for example, infectious diseases.T herefore, the search for alternative classes of inhibitors with greater selectivity towards prokaryotic proteasomes is ongoing.
Proteasomes have been shown to be of great importance to Mtb;t hey help the bacteria survive the nitrosative stress caused by the host's immune response [12] and increaset heir ability to persist in infected mice. [13] Furthermore, the actinobacteria are unusuala mong prokaryotes in that they express proteasomes, meaning that selectivea ction against bacteria of this phylum should be possible. [6b, 14] It is particularly interesting that proteasome inhibitors have been shown to be active on nonreplicating Mtb.T his is important since nonreplicating Mtb (which to al arge extent underlie the need for long treatment times), display reduced protein synthesis, and are left unaffected by most antitranscription or antitranslation agents currently used for treatment.
[15] Only af ew classes of compounds have provent ob ea ctiveo nn onreplicating Mtb,f or example, oxathiazol-2-ones, quinolones, and allylic thiocyanates.
[7c, 16] Mtb proteasome inhibitors displaying speciess electivity,t hus low associated toxicity,a re promising candidates for the development of new antitubercular drugs.
Lin et al. have previously reported that the 1,3,4-oxathiazol-2-one compounds HT1171 and GL5 ( Figure 1 ) act as suicidesubstrate inhibitors of the Mtb proteasome displaying high selectivity over the human proteasome and other proteases,i ncluding trypsin, cathepsin B, and matrix metalloproteases. [7c] They demonstrated that the oxathiazol-2-one moiety acts as an electrophilic warhead, such that the active-site nucleophile, the N-terminal threonine residue, is effectively cyclocarbonylated by an irreversible covalent attack on the heterocycle. [7c, 8b] Moreover,o xathiazolones have been reported to have antimycobacterial activity when they were exploited as carboxylic acid bioisosteres in substituted pyridines and pyrazines. [17] In an attempt to identify an ew generation of species-selective proteasome inhibitors, Gryder et al. investigated the effect of replacing the boronate group on the dipeptide backbone of Bortezomib with an oxathiazol-2-one moiety.U nfortunately, the resulting compound was not active on the Mtb proteasome and only slightly activeo nt he human 20S proteasome. [18] More recently,Y ang et al. assessed the antitubercular activity of as eries of GL5-type oxathiazol-2-ones, together with their dithiazol-3-one analogues,o nt he virulent Mtb H37Rv strain, achieving al owest minimum inhibitory concentration (MIC) value of 4 mgmL À1 (15 mm)f or HT1171.
[16g] These compounds also possessed mycobacterial cell wall permeation properties, and were active against nonreplicating Mtb. They have therefore been proposed as highly interesting antitubercular agents for the synergistic combination treatment of TB.
[7c]
In the present study,w ef urtheri nvestigate the structure-activity relationships of 1,3,4-oxathiazol-2-one derivatives with respect to both their potency as Mtb proteasome inhibitors and their selectivity over the chymotrypsin-like catalytic activity of the human proteasome as an early assessment of potential toxicity. Furthermore, the compounds were optimized with regard to solubility and stability. Finally,a ctivity against replicating and nonreplicating Mtb and cytotoxicity to mammalian cells are reported for ac ollection of selective 5-styryl-1,3,4-oxathiazol-2-one inhibitors.
Results and Discussion
In afirst effort to investigate the chemical space,awide variety of oxathiazol-2-ones were prepared from the corresponding commercially available amides by treatment with chlorocarbonyl sulfenyl chloride at 100 8Cf or 15 min with microwave (MW) heating( MethodA)o ra tr oom temperature overnight (MethodB). Isolated products were thereafter evaluated for proteasome inhibition based on the assay procedures described by Lin et al.
[7c] ( Table 1 , entries 1-23). Compoundsw ere tested for chymotrypsin-like peptidase activity against both the Mtb 20S open-gate proteasome (in which the alpha subunit has an 8-residue deletion at the N-terminus, as described by Lin et al. [8a] )a nd the human 20S proteasome, trackedb y cleavage of the fluorogenic substrate suc-LLVY-7-amino-4-methylcoumarin.
The 5-aryl-substituted 1,3,4-oxathiazol-2-ones in entries 1-4 (Table 1 , 1-4)h ave previously been reported as inhibitors of the Mtb proteasome. [19] To further develop the core structure, we decided to find out if elongated compounds with different spacers could have ap ositive impacto nt he activity. For this purpose, various tethers between the aryl and the heterocyclic warhead were introduced in the 5-position, for example, alkene, alkyne, and methylene linkers. We found that an sp 2 - Figure 1 . Structures of the proteasome inhibitors Bortezomib and oxathiazol-2-one compounds HT1171 and GL5. hybridized carbon directly coupled to the oxathiazol-2-one ring in the 5-postion was crucial for the compound's activity. Additionally,t he introduction of the (E)-alkene linker (entries 17-18) gave inhibitors equally or more potent (17 and 18; IC 50 = 420 and 640 nm,r espectively)t owardt he Mtb proteasome compared to when the aryl was substituted directly onto the oxathiazol-2-one (1-4). More importantly,t his type of compound was not active on the human proteasome (IC 50 > 100 000 nm). For compounds with an alkyne-or carbonyl-containing spacer (19 and 20) , the activities on the Mtb proteasome were slightly lower compared to olefinic inhibitors 17 and 18.M oreover,t hese linkers provided less selective inhibitors. When an sp 3 -hybridized carbon was used as al inker atom, no activity was obtained against the Mtb proteasome, and little or no inhibition was seen towards the human proteasome (entries 9-16). Interestingly,w hen an ethyl bridge was introduced instead of the double bond between the phenyl and oxathiazol-2-one (compare moieties 15 and 17), no inhibition was observed for the Mtb proteasome,b ut the saturated compound instead gained some activity towardt he human proteasome. This suggests that the (E)-double bond is important both for the mycobacterial inhibition and the selectivity over the human proteasome. However,t he allowed substitution pattern of the (E)-alkene linker seems to be slightly constrained;w hen an additional phenyl group was introduced ontot he ethylene linker,n oa ctivity was detected against the Mtb proteasome (entry 23). Instead, compound 23 became am ore potent inhibitor of the human proteasome. > 100 000 > 100 000 --
> 100 000 > 100 000 --
General methodf or the synthesis of 5-substituted oxathiazol-2-ones. Method Ar eagents and conditions:a mide (1.0 equiv), chlorocarbonyls ulfenyl chloride (1.5 equiv), 1,4-dioxane (4.0 mL mmol À1 ), 100 8CM W, 15 min. Method B:a mide (1.0 equiv), chlorocarbonyl sulfenyl chloride (2.0 equiv), THF (4.0 mL mmol À1 ), rt, o/n.
[a] Chemical stability in PBS pH 7.4 at 25 8Ca s%remaining after 24 h. [b] The amide was prepared, and the crude sample was used without furtherp urification.
[c] Reagents and conditions: 14 (1.0 mmol), Dess-Martin periodinane (1.1 mmol), CH 2 Cl 2 (5 mL), 0 8C, 2h.
[ d] General method for the synthesis of 3-substituted dioxazolones. Reagents and conditions:s tarting hydroxamic acid (1.0 equiv), 1,1'-carbonyldiimidazole (1.1 equiv),C H 3 CN (4.0 mL mmol À1 ), 0 8C, 1h.
[ e] The hydroxamic acid was prepared and used as starting material for the dioxazolones ynthesis without furtherp urification.
[ f] Commercially available compound.
[g] Literature value. [18] n.d. = not determined.
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The aryl group of the styryl moiety also seems to be important for the interaction with the Mtb protein. When av inyl group was substituted onto the oxathiazol-2-one, the activity decreased from 420 nm for 17 to 27 000 nm for 21.T his pattern was also observed when aliphatic substituents were introduced (5-8). The effect is probably due to the lack of an aryl group as well as the effect of the hybridization of the carbon directly attached to the oxathiazol-2-one.
To summarize the results depicted in Ta ble 1, it appears that an aryl group conjugated with the oxathiazolones caffold is highly beneficial for the inhibition of the Mtb proteasome (see products 1-4 and 17-22),a nd in particularh igh selectivity over the human proteasome is caused by the presence of the (E)-alkene linker (17 and 18) . This may also be coupled to the loss of activity for the unconjugated 15.
To increase the scope of the investigation,w ew ished to evaluateo ther heterocyclic warheads such as the dioxazolones (Table 1, entries [24] [25] , but these compounds suffered from poor stabilityd ue to rapid hydrolysis. The oxathiazol-2-one was also replaced with aboronic acid functionality ( Table 1 , entries [26] [27] in an attempt to mimic the reversible covalentlybondedw arhead used in Bortezomib. However,t he simple boronic acid analogues were completely inactive on both the Mtb and human proteasomes, suggestingt hat the oxathiazol-2-one moiety is am ore useful electrophile for the inactivation of the target.
As eries of 5-styryl-oxathiazol-2-ones was synthesized to further investigate the effect of the phenyl substitution on the structure-activity relationship of proteasome inhibitors. For this, we developed as ynthetic route where aryl iodides or bromides were used as starting material in am icrowave-assisted Mizoroki-Heck cross-coupling reactionw ith acrylamide to yield the corresponding 3-substituted acrylamides. [20, 21] The final 5-substituted-oxathiazolones were obtained by treating the corresponding amides with chlorocarbonyl sulfenyl chloride (Scheme 1).
Ad iverse set of para-substituted 5-styryl-oxathiazolones were chosen to explore the structuralr equirements of the active site (Table 2 , entries 1-12). The majority of the compounds displayed the same range of inhibiting activity against the Mtb proteasome as 17 and 18 (IC 50 values between 415-1700 nm). The results showednocleartrend in activity for electron-rich and electron-poor aryl substituents, although electron-poorp henyl groups gave slightly better inhibition of the Mtb proteasome compared to electron-rich phenyls. The inhibition of the human proteasome was unfortunately also affected, giving ap oorer selectivity profile. However,b ased on the relative activities for nonstyryl containing 21 and 22 (Table 1, entries [21] [22] , it is evident that the phenyl group is important for inhibition of the Mtb proteasome.
Four of the compounds with the best inhibition and selectivity profiles (Table 2 , 30-33)w erec hosen for further investigation. For these compounds, the corresponding ortho-a nd meta-analogues were synthesized and evaluated in the enzyme activitya ssay (Table 2 , entries 14-21). The para-substituted analogues (Table 2 , entries 3-6) were more active than ortho-a nd meta-substituted analogues on the Mtb proteasome, with IC 50 values in the range of 475-1080 nm.F urthermore, no inhibition of the human proteasome was detected for thesec ompounds. When substituents were introduced in the meta-position (Table 2 , entries 14-17), inhibitory activity of the Mtb proteasome decreased (IC 50 1450-9900 nm)a nd poorer selectivity was observed. The ortho-substituted analogues (entries [18] [19] [20] [21] , despite the same mesomeric contribution as the para-analogues on the styryl moiety,s howed almostn oi nhibition of the Mtb proteasome (IC 50 22 000-> 100 000 nm). The same trend was observed for chloro-functionalized 39 and disubstituted 40 (Table 2, entries 12-13);t he para-substituted compound wasm ore active on the Mtb proteasome and had superior selectivity with regard to the human proteasome.
Overall, the styryl-analogues 28-48 in Ta ble2 displayed good stabilityb ut poor solubility (0.1-7.1 mm). To hopefully improve the solubility of the compounds, as mall series of nitrogen-, oxygen-a nd sulfur-containing heterocyclic derivatives were prepared (Table 3 ). The introductiono ff ive-membered, six-membered, and bicyclic heterocycles into the scaffold generally improved the solubility with retained chemical stability. Furthermore, the heterocyclic analogues were active on the Mtb proteasome, although slightly higher IC 50 values wereo btained compared to the compounds in Table 2 . However,f or the five-membered heterocycle-substituted oxathiazolones, the compounds were not as selective with regard to the human proteasome (Table 3 , entries 3-5 and 9). Based on these promising results for both inhibition and selectivity of the 5-styryl-oxathiazol-2-ones, ac ollectiono fs ynthesized compounds was selected for evaluation of biological activity.A ctive Mtb proteasome inhibitors displaying full to moderate selectivity were tested against av irulent strain of Mtb (H37Rv). Four 5-aryl-oxathiazol-2-ones (Table 4 , entries 1-4) were also testedf or comparison, as well as three known antitubercular agents as ar eference (entries 30-32). Cytotoxicity for mammalian cells was investigated using the Vero cell line (African green monkey kidney cells); the results are reported in Ta ble 4.
The oxathiazolones had little or no activity against replicating bacteria when compared to the known antitubercular agents used as reference (entries 30-32 in Ta ble 4). Af ew com- [b] 735 3300 56.1 88.9
6 54 E; A, 3% [b] 2350 > 10 000 [c] 64.6 n.d.
7 55 E; A, 15 % [b] 1350 > 10 000 [c] 70.6 n.d.
8 56 E; B, 4% [b] 2100 > 10 000 [c] 2.4 n.d. There wasn oc lear difference between the 5-styryl-oxathiazol-2-ones (entries 5-29) and the previously reported 5-aryl-analogues (entries 1-4) or with respectt ot he electronic nature and/or position of the ring substitution. This finding is consistent with the MIC values (15-299 mm)f or as eries of 5-aryl-oxathiazol-2-ones recently tested on the same Mtb strain.
[16g] Compounds demonstrated some cytotoxicity against the Vero cell line, with TC 50 values (concentration required to inhibit growth by 50 %o ver 48 h) in the range of 11-41 mm (when tested). However,t hese results indicate that our new inhibitors are generally 1000/4000-fold less toxic than the approved human proteasome inhibitor Bortezomib (TC 50 less than 10 nm).
[7c] The observed cytotoxicity might be related to the inhibition of the trypsin-like and caspase-like activity of the mammalian proteasome. [22] Alternatively,i tm ight be due to the non-proteasomerelated activity of the styryl oxathiazolone compounds towards other cellular enzymes that catalyze bond cleavage via the same mechanism as the Mtb-proteasome (i.e. nucleophilic attack). On the other hand, ap revious report from Lin et al. demonstrated generally reduced inhibition potency fort he parenta ryl-oxathiazolone inhibitors (e.g. compounds 1-4 included in our study) toward b1a nd b2n on-chymotrypsin-like active sites of the proteasome.
[7c] Additionally high selectivity towardso ther human proteases,i ncluding trypsin, cathepsin B, and matrix metalloproteases was reported for the same proteasome inhibitors.
[7c] However,r ecent research by Bassett et al. has revealed cytotoxicity towards Vero cells for an umber of proteasome inhibitors reported as antitubercular agents. [23] Previous work suggested that the proteasome plays ak ey role during oxidative and nitrosative stress, [12] and that proteasome inhibitors are bactericidal against nonreplicating Mtb subjected to nitrosative stress.
[7c] We therefore determined whether the 5-styryl-oxathiazolone class of compounds had activity against Mtb under nonreplicating conditions. For this we used as tarvation model,i nw hichb acteria are nutrientdeprived for 14 days, [24] to induce the nonreplicating state, after whicht hey are exposed to compounds over 21 days in this state (Figure 2 ).
All four 5-styryl-oxathiazol-2-ones tested (17, 33, 37,a nd 39) were bactericidala gainst nonreplicating Mtb,d isplaying av ery rapid kill (> 4l ogs in 7-14 days). All compounds gave complete sterilization of cultures within 14 days at the lowest concentration tested (20 mm). The 5-(4-chloro)styryl-oxathiazol-2-one inhibitor (39)w as most effective, reducing the colonyforming units (CFU)/mL below the detection limit in only seven days at all concentrations. These data confirmt he selectivity of proteasome inhibitors for nonreplicating over replicating bacteria.
Conclusions
Our results demonstrate that 5-styryl-oxathiazol-2-ones provide ap romising scaffold for Mtb proteasome inhibitors. In the current study we have furthere valuated the structure-activity relationship of oxathiazolones as proteasome inhibitors. We found that conjugated 5-styryl-oxathiazolones are equally or more potent inhibitors of the Mtb proteasome compared to the previously reported 5-aryl-oxathiazolones.A sp art of this investigation we prepared as eries of novel 5-styryl-oxathiazolones from the corresponding aryl iodides or bromides by amicrowave-assisted Mizoroki-Heck coupling with acrylamide. Subsequentc yclization using chlorocarbonyl sulfenyl chloride yielded the oxathiazolones. Our enzyme activity results showedt hat para-substituted 5-styryl-oxathiazol-2-ones were superior to ortho-a nd meta-substitution with regard to Mtb proteasome IC 50 values, as well as their relative lack of effects against the chymotrypsin-like peptidase activity of human pro- The minimum inhibitory concentration (MIC)w as determined against aerobically-grown Mtb H37Rv using a1 0-point serial dilution by optical density (OD) and relative fluorescence units (RFU) measurement. The highest concentrationo fc ompound tested was 20 mm.T he %g rowth was plotted, and ac urve was fitted using the Gompertz fit. The MIC was defined as the minimum concentrationa tw hich growth was completely inhibited and was calculated from the inflectionp ointo ft he fitted curve to the lower asymptote (zero growth). The %inhibition of growth at 20 mm is given. Compounds defined as inactive gave %i nhibition < 20 at 20 mm. Cytotoxicity was measured against the Vero cell line;t he TC 50 is the concentration required to inhibit growth by 50 %o ver 48 h. n.d. = not determined.
[a] Known antitubercular agents were used as reference compounds. [3] ChemistryOpen 2015, 4,342 -362
www.chemistryopen.org teasomes.Wealso produced as mall series of oxathiazolonesin which solubility-enhancing heterocyclic groups were introduced. However,w eg ained solubility at the expense of selectivity regarding the human proteasome.F inally,aselection of the synthesized inhibitors showedr apid bactericidal activity against nonreplicating Mtb,a lthough they were not very active against actively replicating cells. The presentr esultss uggest that this new class of Mtb proteasome inhibitors can be used as the basis for development of novel antitubercular drugs that are effective when protein synthesis of the mycobacteria is drastically reduced, such as in the nonreplicative state or during antibiotic treatment. Further development will include the improvement of the safetyp rofile of this class of Mtb proteasome inhibitors. [30] Experimental Section General Chemistry. Analytical thin-layer chromatography (TLC) was performed on silica gel 60 F-254 plates (Merck) and visualized with UV light. Flash column chromatography was performed on columns prepacked with PHARMA-SIL (5 g/10 g, hydrophilic high surface activity silica, UCT,I nc.,B ristol, USA). 1 19 FNMR were referenced to CFCl 3 used as internal standard (0.0 ppm). The microwave reactions were performed in aB iotage Initiator (Uppsala, Sweden) producing controlled irradiation at 2450 MHz with ap ower of 0-300 W. The reaction temperature was determined using the built-in on-line infrared (IR) sensor.A ll reactions were performed in sealed microwave-transparent process vials designed for 0.5-2, 2-5, or 10-20 mL reaction volumes. Gas chromatography/electron ionization mass spectrometry (GC/EI-MS) was performed on aV arian Saturn 3900/2100 system equipped with aCP-Sil 8CBc apillary column (30 m0.25 mm, 0.25 mm) operating at an EI potential of 70 eV.T he oven temperature (GC) was 70-300 8C. Analytical high-performance liquid chromatography/ www.chemistryopen.org electrospray ionization mass spectrometry (HPLC/ESI-MS) was performed on aG ilson HPLC system (Middleton, USA) with aF innigan AQA ESI quadropole mass spectrometer with electrospray ionization (Thermo Fisher Scientific, Waltham, USA) and using an Onyx Monolithic C18 column 4.6 50mm( Phenomenex, To rrance, USA) with CH 3 CN/H 2 Oi n0 .05 %H COOH as mobile phase at af low rate of 4mLmin À1 or on aD ionex UltiMate 3000 HPLC system (Sunnyvale, USA) with aB ruker amaZon SL ion trap mass spectrometer (Billerica, USA), using aP henomenex Kinetex C18 column (50 3.0 mm, 2.6 mmp article size, 100 p ore size) with CH 3 CN/H 2 Oi n 0.05 %H COOH as mobile phase at af low rate of 1.5 mL min À1 .D etection was by UV (diode array detector) and MS (ESI + mode). Preparative HPLC purification was performed by UV-triggered (254 nm) fraction collection with aD ionex UltiMate 3000 HPLC system, using an Agilent PrepHT Zorbax SB-C8 column (21.2 150 mm, 5 mmp article size) (Santa Clara, USA) with CH 3 CN/H 2 Oi n 0.05 %t rifluoroacetic acid (TFA) as mobile phase. High-resolution mass spectrometry (HRMS) was performed on aM icromass Q-Tof2 mass spectrometer (Waters, Milford, USA) equipped with an electrospray ion source. HRMS data are provided for all novel compounds, unless low ionization level, intrinsic to the physicochemical properties of the specific molecules, did not permit the measurement of the corresponding molecular mass data. However,i n some cases, it was possible to determine the low resolution molecular mass by the Varian Saturn 3900/2100 GC/MS system and/or by the Bruker amaZon SL ion trap mass spectrometer during the LC/MS analysis. All starting materials and reagents are commercially available and were used as received.
General method for the synthesis of 5-substituted oxathiazol-2-one. Method A:Amixture of starting amide (1.0 equiv) and chlorocarbonyl sulfenyl chloride (1.5 equiv) in 1,4-dioxane (4.0 mL mmol À1 ) was irradiated with microwaves at 100 8Cf or 15 min. The mixture was allowed to cool down to rt, and the solvent evaporated at reduced pressure. The crude material was purified by silica gel column chromatography and/or preparative HPLC to give the final compound with purity > 95 %b yH PLC analysis (l = 254 nm).
Method B:Am ixture of starting amide (1.0 equiv) and chlorocarbonyl sulfenyl chloride (2.0 equiv) in freshly distilled THF (4.0 mL mmol À1 )w as stirred o/n at rt. The solvent was evaporated at reduced pressure, and the crude material was purified by silica gel column chromatography and/or preparative HPLC to give the final compound with purity > 95 %byH PLC analysis (l = 254 nm).
5-Phenyl-1,3,4-oxathiazol-2-one (1).
[7c] According to Method A, benzamide (121 mg, 1.0 mmol) was used to give, after preparative HPLC purification, 77 mg (43 %i solated yield) of the title compound as aw hite powder. + adduct not found due to low ionization level.
5-(Pyrazin-2-yl)-1,3,4-oxathiazol-2-one (2). [17] According to Method B, pyrazinamide (123 mg, 1.0 mmol) was reacted with chlorocarbonyl sulfenyl chloride to give, after preparative HPLC purification, 42 mg (23 %i solated yield) of the title compound as white crystals. + adduct not found due to low ionization level.
5-(3-Fluorophenyl)-1,3,4-oxathiazol-2-one (4). + adduct not found due to low ionization level.
5-Cyclopropyl-1,3,4-oxathiazol-2-one (6). According to Method A, cyclopropanecarboxamide (85 mg, 1.0 mmol) was reacted to give, after silica column purification (pentane/EtOAc 100:1), 38 mg (27 % + adduct not found due to low ionization level.
5-Benzyl-1,3,4-oxathiazol-2-one (9) . [25] According to Method A, 2-phenylacetamide (135 mg, 1.0 mmol) was reacted to yield, after preparative HPLC purification, the title compound as aw hite powder (83 mg, 43 %). TLC: R f = 0.39 (isohexane/EtOAc 10:1);L C purity (254 nm + adduct not found due to low ionization level. (E)-5-Styryl-1,3,4-oxathiazol-2-one (17) . [26] According to Method B, trans-cinnamamide (147 mg, 1.0 mmol) was reacted with chlorocarbonyl sulfenyl chloride to give, after silica column purification (pentane/EtOAc 100:0 ! 10:1) and trituration in pentane/EtOAc/MeOH + adduct not found due to low ionization level.
5-
5-Benzoyl-1,3,4-oxathiazol-2-one (19) . [25] In ar ound-bottom flask, Dess-Martin periodinane (467 mg, 1.1 mmol) was added to ap recooled solution (T = 0 8C) of 5-(hydroxy(phenyl)methyl)-1,3,4-oxathiazol-2-one (14)( 209 mg, 1.0 mmol) in anhydrous CH 2 Cl 2 (5 mL). The resulting reaction mixture was stirred 2h at 0 8Ca nd then filtered to remove the formed solid. The mother liquor was washed with H 2 O( 10 mL) and dried on anhydrous Na 2 SO 4 .E vaporation of the solvent under reduced pressure gave 347 mg of the crude material that was triturated with EtOAc for 30 min at rt. Filtration of the formed solid and evaporation of the solvent gave 117mgo f ac olorless oil that was purified by silica column purification In ar ound-bottom flask, SOCl 2 (714 mg, 6.0 mmol) was added to as olution of phenylpropiolic acid (730 mg, 5.0 mmol) in CHCl 3 (10 mL) at rt After addition of DMF (1 drop), the reaction mixture was stirred 1h at rt To the resulting solution was then added 25 %a qN H 4 OH (2.5 mL) at À10 8C. The reaction mixture was allowed to return to rt and stirred 30 min at this temperature. CHCl 3 (10 mL) and H 2 O( 10 mL) where added, the aqueous layer was extracted with CHCl 3 (2 20 mL) and the combined organic phases were dried over Na 2 SO 4 . Evaporation of the solvent under reduced pressure gave 377 mg (52 %i solated yield) of the crude 3-phenylpropiolamide as aw hite solid, which was used for the next step without further purification. + adduct not found due to low ionization level.
5-Vinyl-1,3,4-oxathiazol-2-one (21) . [27] According to Method B, acrylamide (107 mg, 1.5 mmol) was reacted with chlorocarbonyl sulfenyl chloride to give, after two silica column purification ( + adduct not found due to low ionization level.
(E)-5-(1,2-Diphenylvinyl)-1,3,4-oxathiazol-2-one (23). 2-Phenyltrans-cinnamic acid (224 mg, 1.0 mmol) and 1,1'-carbonyldiimidazole (357 mg, 2.2 mmol) were dissolved in DMF (5 mL) and the mixture was stirred at rt. After 30 min, NH 4 HCO 3 (316 mg, 4.0 mmol) was added and the resulting suspension was stirred at rt for 3d.E tOAc (50 mL) was added, and the organic phase was washed with H 2 O( 220 mL) and brine (20 mL). Evaporation of solvent gave 212 mg of the crude corresponding amide, purified by silica column chromatography (pentane/EtOAc 1:1 ! 3:1) to afford 150 mg (67 %i solated yield) of 2-phenyl-trans-cinnamamide as white crystals. TLC: R f = 0.63 (pentane/EtOAc = 1:1);G C/MS purity: 99 %; 1 (E)-3-Styryl-1,4,2-dioxazol-5-one (25) . trans-Cinnamic acid (296 mg, 2.0 mmol) and 1,1'-carbonyldiimidazole (486 mg, 3.0 mmol) were dissolved in THF (8 mL), and the mixture was stirred at rt. After 1h,h ydroxylamine hydrochloride (278 mg, 4.0 mmol) was added, and the resulting suspension was stirred at rt for 2d.5%a qK HSO 4 (30 mL) was added, and the mixture was extracted with EtOAc (2 30mL). The collected organic phases were washed with brine (30 mL) and dried over Na 2 SO 4 .E vaporation of solvent gave 280 mg (86 %i solated yield) of the corresponding N-hydroxycinnamamide as ap ale pink solid, used in the next step without further purification. LC purity ( + adduct not found due to low ionization level.
General method for the synthesis of 2-substituted acrylamide. Method C( Mizoroki-Heck reaction, electron-rich iodide) As uitable microwave vial was loaded with solid reactants and reagents:s tarting iodide (1.0 equiv), acrylamide (2.0 equiv), palladium(II) acetate (0.05 equiv), and tri-tert-butylphosphonium tetrafluoroborate (0.10 equiv). CH 3 CN (4.0 mL mmol
À1
)w as added, followed by liquid reactants:s tarting iodide (1.0 equiv,i nc ase). Oxygen was removed by bubbling gaseous nitrogen into the resulting mixture for 15 min, then triethylamine (3.0 equiv) was added, the vial was capped, and the reaction mixture was irradiated with microwaves at 120 8Cf or 15 min. The mixture was allowed to cool down to rt, and the collected crude material was purified by silica gel column chromatography to give the desired 3-substituted acrylamide.
Method D( Mizoroki-Heck reaction, electron-poor iodide) As uitable microwave vial was loaded with solid reactants and reagents:s tarting iodide (1.0 equiv), acrylamide (2.0 equiv), and palladium(II) acetate (0.05 equiv). CH 3 CN (4.0 mL mmol À1 )w as added, followed by liquid reactants:s tarting iodide (1.0 equiv,i nc ase). Oxygen was removed by bubbling gaseous nitrogen into the resulting mixture for 15 min, then triethylamine (3.0 equiv) was added, the vial was capped, and the reaction mixture was irradiated with microwaves at 120 8Cf or 15 min. The mixture was allowed to cool down to rt, and the collected crude material was purified by silica gel column chromatography to give the desired 3-substituted acrylamide.
Method E( Mizoroki-Heck reaction, electron-poor bromide) As uitable microwave vial was loaded with solid reactants and reagents:s tarting bromide (1.0 equiv), acrylamide (1.5 equiv), trans-bis(acetato)-bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) (0.05 equiv), and NaOAc (3.0 equiv). Dry DMF (4.0 mL mmol À1 )w as added, followed by liquid reactants:s tarting bromide (1.0 equiv,i nc ase). The vial was capped, and the reaction mixture was irradiated with microwaves at 140 8Cf or 15 min. The mixture was allowed to cool down to rt, and the collected crude material was purified by silica gel column chromatography to give the desired 3-substituted acrylamide.
(E)-5-(4-Methoxystyryl)-1,3,4-oxathiazol-2-one (28). According to Method C, 4-iodoanisole (234 mg, 1.0 mmol) was used as starting iodide in the Mizoroki-Heck reaction. After microwave irradiation, the reaction mixture was cooled down to 0 8Ca nd the collected precipitate was washed with cold CH 3 CN (3 mL) and dried by vacuum to give 139 mg of the crude corresponding acrylate, that was purified by silica column chromatography (EtOAc/MeOH 100:5 ! 100:10) to afford 133 mg (75 %i solated yield) of (E)-3-(4-methoxyphenyl)acrylamide as aw hite powder.T LC: R f = 0.34 (EtOAc); LC purity (254 nm): 95 %; + adduct not found due to low ionization level.
(E)-5-(4-Methylstyryl)-1,3,4-oxathiazol-2-one (30) . According to Method C, 1-iodo-4-methylbenzene (218 mg, 1.0 mmol) was used as starting iodide in the Mizoroki-Heck reaction. After microwave irradiation, the reaction mixture was cooled down to 0 8C, and the collected precipitate was washed with cold CH 3 CN (3 mL) and (E)-5-(4-Ethylstyryl)-1,3,4-oxathiazol-2-one (31). According to Method C, 1-ethyl-4-iodobenzene (232 mg, 1.0 mmol) was used as starting iodide in the Mizoroki-Heck reaction. After microwave irradiation, the reaction mixture was cooled down to 0 8C, and the collected precipitate was washed with cold CH 3 CN (3 mL) and dried by vacuum to give 170 mg of the crude corresponding acrylate, which was purified by silica column chromatography (EtOAc/MeOH 100:0 ! 100:10) to afford 88 mg (50 %i solated yield) of (E)-3- www.chemistryopen.org 1.0 mmol) was used as starting iodide in the Mizoroki-Heck reaction. After microwave irradiation, the reaction mixture was cooled down to 0 8C, and the collected precipitate was washed with cold CH 3 CN (3 mL) and dried by vacuum. The crude corresponding acrylate was purified by silica column chromatography (EtOAc/MeOH 1:0 ! 10:1) to afford 124 mg (60 %i solated yield) of (E)-methyl 4- (E)-4-(2-(2-Oxo-1,3,4-oxathiazol-5-yl)vinyl)benzonitrile (37). According to Method D, 4-iodobenzonitrile (229 mg, 1.0 mmol) was used as starting iodide in the Mizoroki-Heck reaction. After microwave irradiation, the reaction mixture was cooled down to rt, and the formed Pd black was removed by filtration through Celite. Evaporation of the solvent gave the crude corresponding acrylate, which was purified by silica column chromatography (double purification:1 st EtOAc, 2 nd pentane/EtOAc 1:1 ! 0:1) to afford 123 mg of a1 :2 mixture of (E)-3-(4-cyanophenyl)acrylamide and starting acrylamide as white apowder.TLC:Mizoroki-Heck product (E)-4-(2-(2-Oxo-1,3,4-oxathiazol-5-yl)vinyl)benzaldehyde (38). According to Method D, 4-iodobenzaldehyde (232 mg, 1.0 mmol) was used as starting iodide in the Mizoroki-Heck reaction. After microwave irradiation, the reaction mixture was cooled down to rt, and the formed Pd black was removed by filtration through Celite. Evaporation of the solvent gave the crude corresponding acrylate, which was purified by silica column chromatography (double purification:1 st EtOAc, 2 nd pentane/EtOAc 1:1 ! 0:1) to afford 100 mg of a2 :3 mixture of (E)-3-(4-formylphenyl)acrylamide and starting acrylamide as awhite powder.TLC:Mizoroki-Heck product + adduct not found due to low ionization level.
(E)-5-(4-Chlorostyryl)-1,3,4-oxathiazol-2-one (39). Accordingt o MethodD,1 -chloro-4-iodobenzene (238 mg, 1.0 mmol) was used as starting iodide in the Mizoroki-Heck reaction. After microwave irradiation, the reaction mixture was cooledd own to 0 8C, and the collected precipitate was washed with cold CH 3 CN (3 mL) and dried by vacuum.T he crude corresponding acrylate was purified by silica column chromatography (EtOAc/MeOH 1:0 ! 10:1) to afford 123 mg (68 %i solatedy ield) of (E) + adduct not foundd ue to low ionization level.
(E)-5-(2,5-Dichlorostyryl)-1,3,4-oxathiazol-2-one (40). According to Method D, 1,4-dichloro-2-iodobenzene (273 mg, 1.0 mmol) was used as starting iodide in the Mizoroki-Heck reaction. After microwave irradiation, the reaction mixture was cooled down to rt, and the formed Pd black was removed by filtration through Celite. (E)-5-(2-Ethylstyryl)-1,3,4-oxathiazol-2-one (46). According to Method E, 1-bromo-2-ethylbenzene (218 mg, 1.0 mmol) was used as starting bromide in the Mizoroki-Heck reaction. After microwave irradiation, the reaction mixture was cooled down to rt, and filtered through ap lug of cotton. The reaction mixture was then ex- (E)-5-(2-(Thiophen-2-yl)vinyl)-1,3,4-oxathiazol-2-one (51). According to Method C, 2-iodothiophene (210 mg, 1.0 mmol) was used as starting iodide in the Mizoroki-Heck reaction. After 15 min of microwave irradiation (T = 120 8C), the reaction mixture was irradiated for additional 30 min at the same temperature to afford full conversion. The resulting reaction mixture was cooled down to rt, and the formed Pd black was removed by filtration through silica gel (CH 3 CN!EtOAc!EtOAc/MeOH 10:1). Evaporation of the solvent gave the crude corresponding acrylate, which was purified by precipitation from CH 3 OH/H 2 Ot oa fford7 0mg( 46 %i solated yield) of (E)-3-(thiophen-2-yl)acrylamide as an off-white solid. TLC: Proteasome cloning, expression, and purification. Thes equences fort he open-gate alpha [8a] (Rv2109c residues 9-240) and as lightly truncated beta (Rv2110c) (residues1 -285) subunitso ft he M. tuberculosis proteasome were amplifiedb yP CR from total DNA of Mtb strain H37Rv [28] usingt he polymeraseP fu Ultra( AgilentT echnologies, La Jolla, USA).T he C-terminuso ft he beta subunit was modifiedt oi ncorporate a6 -histidinet ag aftert he terminal glycine residue. [8a] Theg enesw erei nserted into the vectorp RSF Duet-1, whichi sav ectorf or coexpressing two proteins,b othc ontrolled by T7 promoters,f romN ovagen (MerckMillipore,D armstadt,G ermany), andc lonedi nE. coli To p10c ells (Invitrogen,C arlsbad, USA).
Expression and purification were performed as previously described. [8a] Briefly,6Lc ultures of E. coli BL21(DE3) cells in Luria Bertani broth with 30 mg/mL kanamycin were grown for 20-22 ha t 37 8Ca fter induction with 0.4 mm isopropyl beta-D1 thiogalactopyranoside. The cells were harvested by centrifugation, resuspended in lysis buffer (50 mm Na 3 PO 4 ,p H8,3 00 mm NaCl, 10 mm imidazole with 0.25 mg mL À1 lysozyme, 0.02 mg mL À1 RNase, and 0.01 mg mL À1 DNase), incubated 30 min at rt and lysed by passage through aC onstant Cell Disruption System (Constant Systems Ltd, Daventry,U K) at 2kBar.F ull proteasome molecules were isolated from the cleared lysate with 1mLNi-Sepharose (GE-Healthcare, Uppsala, Sweden), and eluted with 250 mm imidazole. The buffer was exchanged on an Econo-Pac 10DG desalting column (Bio-Rad, Hercules, USA) to 10 mm Tris pH 7.5, 100 mm NaCl before af inal purification step by size-exclusion chromatography on aH iLoad 16/60 Superdex 200 column (GE Healthcare, Little Chalfront, UK) equilibrated with the same buffer.The fractions containing the proteasome as analyzed by SDS-PAGE were pooled and concentrated to 1mgmL À1 (measured by A280, extinction coefficient 33 810 m À1 cm À1 )i naVivaspin 20, molecular weight cut-off 100 kDa (Sartorius Stedin Biotech, Goettingen, Germany).
Proteasome assay. The protein production and assay were based on that of Lin et al.
[8b] Both Mtb and human proteasomes were assayed in 20 mm Hepes, 0.5 mm EDTAp H7.5, with 25 mm suc-LLVY-AMC (Bachem AG, Switzerland) as substrate, in af inal volume of 100 mLo naw hite 96-well assay plate (Cliniplate, Thermo Fisher Scientific OY,F inland). The increase in fluorescence caused by cleavage of AMC (7-amino-4-methylcoumarin) was measured using aF luoroskan Ascent fluorescent plate reader (Thermo Fisher Scientific OY,F inland) equipped with a3 90 nm filter for excitation and 460 nm filter for emission. Human 20S proteasome (Boston Biochemicals, USA) was assayed at 1nmconcentration in the presence of at enfold excess of human PA28 activator (Boston Biochemicals), as recommended by the manufacturer.T he Mtb proteasome was assayed at ac oncentration of 2nm.T he assay was performed as follows. Threefold dilutions of inhibitor (10 mm stock solution in DMSO) from an initial concentration of 100 mm were performed on the assay plate in buffer containing the above concentrations of enzyme;t he final volume in the well after dilution was 96 mL. The plate was sealed and preincubated at rt for 3hfor Mtb proteasome or 1h for human proteasome. Next, substrate (5 mLo f5 00 mm in ab uffer made from a1 0mm stock solution in DMSO) was added, and the fluorescence read in the plate reader immediately (t = 0), then after 3hfor the Mtb proteasome and after 1hfor the human proteasome. The t = 0v alue was subtracted from the final value, and plotted against the logarithm of the inhibitor concentration; the data were fitted to the standard IC 50 equation using GraphPad Prism 5( GraphPad Software Inc.,USA).
Minimum inhibitory concentration (MIC).
The MIC were determined as previously described [29] in Middlebrook 7H9 medium containing 10 %v /v OADC (oleic acid, bovine serum albumin, d-glucose, catalase;B ecton Dickinson, USA) and 0.05 % w/v Tween 80.
Briefly,c ompounds were tested in 10-point, two-fold serial dilutions with the highest concentration of 20 mm against Mtb H37Rv expressing af luorescent protein (DsRed). Growth was measured using OD 590 and RFU after 5d.C urves were fitted using the Gompertz function, with MIC defined as the minimum concentration required to inhibit growth. Data are reported for optical density at 590 nm (OD 590 )and relative fluorescence units (RFU). Cytotoxicity assay. Cytotoxicity was monitored against Vero African green monkey kidney epithelial cells (ATCC CCL-81) grown in DMEM, High Glucose, GlutaMAX (Invitrogen), supplemented with 10 %F BS, and penicillin-streptomycin solution (Gibco). The assay was run in 96-well plates using a1 0-point, serial dilution curve. Cell viability was measured after 48 hu sing Cell Titer Glo (Promega), and growth inhibition curves were fitted using the LevenbergMarquardt algorithm. The TC 50 was defined as the compound concentration that gave 50 %inhibition of growth.
Determination of solubility in PBS (pH 7.4). HPLC analyses were performed using aS himadzu 10 As ystem with aS CL-10Avp controller,2LC-10AD pumps with a0 .5 mL gradient mixer at the high pressure side, aS IL-10 A( rebuilt to also run 96-well plates), aC MA 260 Degasser,a nd aW aters PDA 996 Photodiode Array Detector.A Zorbax Eclipse XDB-C8, 5 mm, 2.1 50mmc olumn was utilized from Dalco Chromtech AB (Sollentuna, Sweden) with CH 3 CN/H 2 Oi n 0.05 %T FA as mobile phase and 1mLmin
À1
.T he chromatograms were registered at the wavelengths 230, 254, and 280 nm. All solutions containing the sample compound were prepared from 10 mm DMSO stock solutions stored in glass vials at ambient temperature. High standards (HS) were made by diluting the DMSO stock solution 200 times with CH 3 CN + PBS pH 7.4 (1 + 1), obtaining a5 0m msolution. Low standards (LS) were prepared by diluting HS 20 times with CH 3 CN + PBS pH 7.4 (1 + 1), obtaining a2 .5 mm solution. The HS solution was chromatographed as econd time after 24 ht od etermine the chemical stability.I tw as very important to exchange the septa after the first injection to avoid evaporation of the CH 3 CN. The solubility solutions were prepared by diluting the DMSO stock solution 100 times with PBS pH 7.4, obtaining an ominal concentration of 100 mm.T he solutions were left for 18 ha t ambient temperature before filtration. When filtering the sample solution, the first 0.1 mL was discarded, and the rest was collected. The solubility was determined using at wo-point calibration curve forced through the origin. To evaluate the quality of the standard curve, the quotient of the area of HS to the LS was also calculated. The optimal quotient should equal the value of the concentration ratio, that is, 20.0. When evaluating the solubility,t he wavelength used was that which gives the area quotient closest to 20. The stability (given in percent remaining) was obtained by multiplying the area after the 24 hr un by 100 and dividing it by the area of the first HS injection.
Abbreviations used. MW,m icrowaves; Mtb, Mycobacterium tuberculosis;M DR, multidrug resistant;X DR, extensively drug resistant; TDR, totally drug resistant;M IC, minimum inhibitory concentration; CFU, colony forming units Notes. The authors declare no competing financial interest.
